Seismic Therapeutic, a Cambridge, Mass.-based machine learning immunology company, has closed a $121 million Series B financing.
The round was led by Bessemer Venture Partners, with participation from new investors including Amgen Ventures, Codon Capital, Alexandria Venture Investments, Gaingels, and GC&H, along with participation from existing investors.
Bessemer Venture Partners is a venture capital firm that invests in enterprise, consumer, and healthcare early-to-late-stage startups. The firm helps entrepreneurs lay strong foundations to build and forge long-standing companies. With more than 145 IPOs and 300 portfolios, Bessemer supports founders and CEOs from their early days through every stage of growth. Bessemer’s has $20 billion of assets under management and has teams of investors and partners located in Tel Aviv, Silicon Valley, San Francisco, New York, London, Hong Kong, Boston, and Bangalore.
Seismic Therapeutic Use of Funds
The company plans to use the proceeds to advance its two lead programs through Phase 1 proof-of-mechanism trials. The two lead programs include a pan-immunoglobulin (Ig) G protease sculpting enzyme candidate (S-1117) and a PD-1 agonist:Fc gamma receptor IIb selective Dual-cell Bidirectional antibody candidate (S-4321).
The funding will also support the growth of the pipeline and further expansion of its proprietary machine learning-enabled IMPACT platform.
About Seismic Therapeutic
Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics drug discovery and development process. The company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. Seismic Therapeutic’s IMPACT platform “parallelizes” interdisciplinary components of drug discovery to generate drug molecules on an unprecedented scale that are engineered to be better therapeutics to treat autoimmune diseases. The company believes its unique approach to applying machine learning to biologics drug discovery will create positive change in the autoimmune landscape and the lives of patients.
Company: Seismic Therapeutic, Inc.
Round: Series B
Funding Month: December 2023
Lead Investors: Bessemer Venture Partners
Additional Investors: Amgen Ventures, Codon Capital, Alexandria Venture Investments, Gaingels, and GC&H
Company Website: https://seismictx.com/
Software Category: Immunology Drug Discovery